Companies / Gain Therapeutics, Inc.

Gain Therapeutics, Inc.

Nasdaq: GANXCIK 1819411BETHESDA, MD

Financials · FY2023

Revenue$55.2K
Net income$-20.16M
Total debt$343.7K
Cash$13.08M
Diluted EPS$-0.61
Shares outstanding43.6M

Ownership

43.6M shares outstanding · as of Jul 31, 2026
19.7%Institutions
Ownership
Institutions19.67%8,582,889
Public float80.33%35,060,730

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 2

View all →
Insider% of sharesShares
Fuggetta GianlucaSee Remark
——
Mack GeneCEOCEO, President · Director
——

Institutional holders 48

View all →
HolderValue% of shares
Marshall Wace, LLP$3.43M4.06%
Potomac Capital Management, Inc.$3.25M2.31%
Jones Financial Companies Lllp$2.26M1.61%
Susquehanna International Group, LLP$2.20M1.57%
Vanguard Group Inc$1.84M1.31%
DME Capital Management, LP$1.82M1.30%
Geode Capital Management, LLC$868.5K1.02%
Jane Street Group, LLC$780.3K0.56%
BlackRock, Inc.$558.2K0.63%
Cresset Asset Management, LLC$515.2K0.37%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 24, 2026Mack Gene
CEO
GrantEmployee Stock Option (right to buy)—+200K
200,000
0.46% of shares
low
Mar 24, 2026Fuggetta Gianluca
Executive
GrantEmployee Stock Option (right to buy)—+50K
50,000
0.11% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
GANXCommon StockEquity36269B105BBG00W7D7CJ9